Hematological Oncology Journal Citation Rate 2026

ISSN 0278-0232 eISSN 1099-1069 Wiley GB

Q3 Quartile Verified Publisher

About Hematological Oncology
{# Self-contained "answer block": one dense, LLM-quotable paragraph stating every core fact with an explicit as-of year, server-rendered and unique per journal. This is the canonical fact statement — other sections add narrative, they do not restate these numbers. #}

Hematological Oncology (HO) is a peer-reviewed academic journal covering CAR-T cell therapy research and CNS Lymphoma Diagnosis and Treatment, published by Wiley in GB, catalogued under ISSN 0278-0232 (e-ISSN 1099-1069). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 0.47 (Q3 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$4220 USD). OpenAlex records 6,026 works and 41,757 citations, with an h-index of 73.

Hematological Oncology Citation Rate 2026 — In Context

Hematological Oncology has a 2025 2-Year Citation Rate (OpenAlex) of 0.47, placing it in the Q3 quartile within the CAR-T cell therapy research research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.

Hematological Oncology operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.

Researchers looking to publish in Hematological Oncology should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Hematological Oncology against similar journals in the field, use our journal comparison tool.

Submission Tips for Hematological Oncology
  • Budget $4220 for the Article Processing Charge. Check if your institution or funder covers OA fees.
  • This journal covers CAR-T cell therapy research, CNS Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Hematological Oncology Compares
Citation Rate vs Field Avg
-91%
Field avg: 5.24
APC vs Field Avg
+15%
Field avg: $3672

Compared against 24 journals in the same research areas.

ISSN (Print) 0278-0232
ISSN (Online) 1099-1069
Publisher Wiley
Country United Kingdom
APC / Cost $4220 USD
In-depth profile & metrics

Hematological Oncology is published by Wiley and based in United Kingdom. It runs on a subscription or hybrid model with an article-processing charge of USD 4220.

In our subject taxonomy, Hematological Oncology is classified under CAR-T cell therapy research, CNS Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and Lymphoma Diagnosis and Treatment.

Hematological Oncology is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.

Its most recent citation rate stands at 0.468.

Research Areas
Links
Frequently Asked Questions about Hematological Oncology

Hematological Oncology does not hold a Clarivate (JCR) Impact Factor on JournalsHub. Its 2-year citation rate, computed from OpenAlex open citation data, is 0.468 — an open proxy for citation impact, not the licensed JCR Impact Factor.

No, Hematological Oncology is not an open access journal.

The Article Processing Charge (APC) for Hematological Oncology is $4220 USD.

Hematological Oncology is published by Wiley.

Hematological Oncology shows strong legitimacy signals: it is indexed in OpenAlex. Indexing in recognised databases such as Scopus and DOAJ is a reliable indicator of a peer-reviewed, non-predatory journal, because predatory titles are typically excluded from them. Always confirm the journal's scope and editorial board fit your work before submitting.

The ISSN of Hematological Oncology is 0278-0232. Its electronic ISSN (eISSN) is 1099-1069.

Hematological Oncology sits in the Q3 quartile based on its latest impact factor of 0.47, ranked across all journals in our database.
Live Indexing Status
Updated April 2026

Track real-time indexing metrics to ensure this journal meets your academic requirements.

OpenAlex
Verified
DOAJ
Non-OA
Predatory Check
Clean
Citation Rate
0.468
2-Year Citation Rate (OpenAlex) · 2025
Historical Trend
Initial data points only
Citation Rate by Year
Year Value Source
2025 0.468 2-Year Mean Citedness (OpenAlex)

Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.

Compare Journals

Compare Hematological Oncology against similar publications in its field:

Related Journals in Your Field

Metadata

Last updated: Apr 24, 2026

Updated by: openalex_bulk

OpenAlex ID: S23714410

Get weekly updates for CAR-T cell therapy research journals

Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.

Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now
Compare 0 Open → Clear
Save your viewing history
You've browsed several journals this session. Sign in to track them in one place and get weekly impact-factor updates.
Save with Google